By Padmanabhan Ananthan March 9 (Reuters) - U.S. drugmaker Pfizer said on Monday its experimental drug for a chronic skin ...

China has approved a new obesity treatment from Pfizer Inc., heightening competition in a market poised to become even more ...

Pfizer is ramping up plans for tilrekimig after a phase 2 win raised hopes that the once-monthly trispecific antibody could hold its own against approved eczema drugs. | Pfizer is ramping up plans for ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from a Phase 2 study investigating tilrekimig (PF-07275315) ...

Explore Pfizer’s evolving pipeline strategy, expanding into oncology and obesity to drive growth beyond its COVID-19 success.

By Andrew Silver SHANGHAI, March 6 (Reuters) - China has approved Pfizer's GLP-1 treatment Xianweiying for long-term weight ...

One of the most powerful voices in the biopharma industry, Pfizer CEO Albert Bourla, Ph.D., has weighed in with sharp ...

Pfizer CEO ‌Albert ‌Bourla on Monday ​flagged issues with the leadership of ‌the ⁠U. Food and ⁠Drug Administration's vaccine ...

Is Pfizer's 6% yield a rare opportunity hiding in plain sight, or are investors overlooking a major risk that could reshape its future?

Pfizer said its Phase 2 study of tilrekimig (PF-07275315), a trispecific antibody for atopic dermatitis, showed positive ...

Pfizer said a Phase 2 study of tilrekimig met its key goals in adults with moderate to severe atopic dermatitis, the most common form of eczema, and that it plans to accelerate the drug candidate into ...

Historical patterns indicate that abrupt fluctuations in the market can impact any firm, regardless of its seeming dominance.